Clinical Trial Update: Pradaxa Tablet Proton Pump Inhibitor (PPI) Bioavailability (BA) Study in Japan [Phase 1]

View source ↗

Summary

Phase 1 study update on Pradaxa tablet bioavailability when co-administered with proton pump inhibitors in Japan; completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-alcoholic Fatty Liver Disease

Drugs mentioned

• Pradaxa (dabigatran etexilate)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Non-alcoholic Fatty Liver Disease | Phase 1 | Status: COMPLETED | Results posted: 2019-01-16